JP2018516851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516851A5 JP2018516851A5 JP2017550548A JP2017550548A JP2018516851A5 JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5 JP 2017550548 A JP2017550548 A JP 2017550548A JP 2017550548 A JP2017550548 A JP 2017550548A JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- antibody
- formula
- integer
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)[C@@](C(N[C@@](CCCNC(N)=O)C(C)=O)=O)NC(*(C)(C)N(C(CC1C)=O)C1=O)=O Chemical compound CC(C)[C@@](C(N[C@@](CCCNC(N)=O)C(C)=O)=O)NC(*(C)(C)N(C(CC1C)=O)C1=O)=O 0.000 description 3
- ROEXBULBZKICBC-KRQJBFIFSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)[C@@H](C)[C@@H]1C)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@]1(C)O)=O)N(C)C(c(cc1)cc(S(C)(=O)=O)c1NNC)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)[C@@H](C)[C@@H]1C)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@]1(C)O)=O)N(C)C(c(cc1)cc(S(C)(=O)=O)c1NNC)=O ROEXBULBZKICBC-KRQJBFIFSA-N 0.000 description 1
- LHKUAZUPONJFED-BJWVSRTKSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]1OC)cc2OC)c2Cl)=O)[C@@H](C)[C@@H](C)[C@H](C)[C@@H](C)C[C@]1(NC(O)=O)O)=O)NC Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]1OC)cc2OC)c2Cl)=O)[C@@H](C)[C@@H](C)[C@H](C)[C@@H](C)C[C@]1(NC(O)=O)O)=O)NC LHKUAZUPONJFED-BJWVSRTKSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021044152A JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139044P | 2015-03-27 | 2015-03-27 | |
| US62/139,044 | 2015-03-27 | ||
| US201562252239P | 2015-11-06 | 2015-11-06 | |
| US62/252,239 | 2015-11-06 | ||
| PCT/US2016/024343 WO2016160615A1 (en) | 2015-03-27 | 2016-03-25 | Maytansinoid derivatives, conjugates thereof, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021044152A Division JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516851A JP2018516851A (ja) | 2018-06-28 |
| JP2018516851A5 true JP2018516851A5 (https=) | 2019-05-23 |
| JP6948950B2 JP6948950B2 (ja) | 2021-10-13 |
Family
ID=55650789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550548A Active JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
| JP2021044152A Withdrawn JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021044152A Withdrawn JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160375147A1 (https=) |
| EP (1) | EP3273998B1 (https=) |
| JP (2) | JP6948950B2 (https=) |
| KR (2) | KR20240142591A (https=) |
| CN (2) | CN115645543A (https=) |
| AU (1) | AU2016243527B2 (https=) |
| BR (1) | BR112017020149A8 (https=) |
| CA (1) | CA2978340C (https=) |
| CL (1) | CL2017002422A1 (https=) |
| CO (1) | CO2017010890A2 (https=) |
| EA (1) | EA034950B1 (https=) |
| IL (1) | IL254267B (https=) |
| MX (2) | MX386328B (https=) |
| PH (1) | PH12017501780A1 (https=) |
| SG (1) | SG11201707148PA (https=) |
| WO (1) | WO2016160615A1 (https=) |
| ZA (1) | ZA201706040B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| EA034950B1 (ru) * | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| US11384104B2 (en) | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2017132173A1 (en) | 2016-01-25 | 2017-08-03 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018102304A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| FI3635009T3 (fi) | 2017-06-07 | 2026-04-07 | Regeneron Pharma | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| IL305268A (en) * | 2017-11-30 | 2023-10-01 | Centurion Biopharma Corp | Maytansinoid-based drug delivery systems |
| MX2020011487A (es) | 2018-04-30 | 2020-12-07 | Regeneron Pharma | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| CN112638426B (zh) * | 2018-09-21 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| US20220040319A1 (en) | 2019-02-21 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| IL319200A (en) | 2020-04-16 | 2025-04-01 | Regeneron Pharma | Antibody-drug conjugates prepared using Diels-Alder compression methods |
| AU2021366691B2 (en) | 2020-10-22 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| CA3198294A1 (en) | 2020-11-10 | 2022-05-19 | Thomas Nittoli | Selenium antibody conjugates |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| NZ565075A (en) | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| WO2007021674A2 (en) | 2005-08-09 | 2007-02-22 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| KR101352222B1 (ko) | 2005-12-22 | 2014-02-04 | 백스터 인터내셔널 인코포레이티드 | 의료용 제품에서 비-내독소 발열성 오염물을 보다 잘검출할 수 있는 개선된 단핵구 활성화 시험 |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20140116546A (ko) | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| EP2374481B1 (en) | 2008-07-21 | 2015-11-04 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JP5954789B2 (ja) | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| EP2486023A4 (en) | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| MY162780A (en) | 2010-09-01 | 2017-07-14 | Bayer Ip Gmbh | N-(Tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides and use thereof as herbicides |
| CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| CN103269712B (zh) | 2010-11-03 | 2016-09-21 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
| JP6215194B2 (ja) | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103648532A (zh) * | 2011-06-21 | 2014-03-19 | 伊缪诺金公司 | 具有肽连接子的新型美登木素生物碱衍生物及其偶联物 |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CN104244718A (zh) | 2011-12-05 | 2014-12-24 | 伊格尼卡生物治疗公司 | 抗体-药物缀合物以及相关化合物、组合物和方法 |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| MX2014015682A (es) | 2012-06-19 | 2015-07-23 | Polytherics Ltd | Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos. |
| FI2911699T4 (fi) | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| NO2789793T3 (https=) | 2012-10-24 | 2018-01-27 | ||
| US10131682B2 (en) * | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| MX379256B (es) * | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| SG11201509982UA (https=) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| KR102252925B1 (ko) * | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| WO2015081281A1 (en) | 2013-11-26 | 2015-06-04 | Segway Orthopaedics, Inc. | Surgical blade with viewing aperture |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US9562059B2 (en) | 2013-12-02 | 2017-02-07 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| EA034950B1 (ru) | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| WO2017132173A1 (en) | 2016-01-25 | 2017-08-03 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2016
- 2016-03-25 EA EA201700464A patent/EA034950B1/ru unknown
- 2016-03-25 KR KR1020247030839A patent/KR20240142591A/ko active Pending
- 2016-03-25 BR BR112017020149A patent/BR112017020149A8/pt not_active Application Discontinuation
- 2016-03-25 CN CN202210829028.0A patent/CN115645543A/zh active Pending
- 2016-03-25 MX MX2017012380A patent/MX386328B/es unknown
- 2016-03-25 EP EP16714199.3A patent/EP3273998B1/en active Active
- 2016-03-25 JP JP2017550548A patent/JP6948950B2/ja active Active
- 2016-03-25 SG SG11201707148PA patent/SG11201707148PA/en unknown
- 2016-03-25 US US15/081,759 patent/US20160375147A1/en not_active Abandoned
- 2016-03-25 KR KR1020177030678A patent/KR102708103B1/ko active Active
- 2016-03-25 WO PCT/US2016/024343 patent/WO2016160615A1/en not_active Ceased
- 2016-03-25 AU AU2016243527A patent/AU2016243527B2/en active Active
- 2016-03-25 CN CN201680030443.2A patent/CN107995912A/zh active Pending
- 2016-03-25 CA CA2978340A patent/CA2978340C/en active Active
-
2017
- 2017-09-01 IL IL254267A patent/IL254267B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06040A patent/ZA201706040B/en unknown
- 2017-09-26 CL CL2017002422A patent/CL2017002422A1/es unknown
- 2017-09-27 PH PH12017501780A patent/PH12017501780A1/en unknown
- 2017-09-27 MX MX2021008101A patent/MX2021008101A/es unknown
- 2017-10-26 CO CONC2017/0010890A patent/CO2017010890A2/es unknown
-
2019
- 2019-12-12 US US16/712,941 patent/US20200385402A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021044152A patent/JP2021113191A/ja not_active Withdrawn
- 2021-11-16 US US17/528,144 patent/US12297207B2/en active Active
-
2025
- 2025-03-28 US US19/093,440 patent/US20250223299A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516851A5 (https=) | ||
| KR102708103B1 (ko) | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 | |
| JP6934010B2 (ja) | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 | |
| JP6133431B2 (ja) | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 | |
| JP6417421B2 (ja) | 荷電連結体及び共役体のためのその使用 | |
| KR20250004952A (ko) | 캄프토테신 접합체 | |
| JPWO2019240288A1 (ja) | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | |
| JP7573262B2 (ja) | 細胞結合分子の共役のための架橋連結体 | |
| TWI654179B (zh) | 放射性醫藥複合物 | |
| SG194567A1 (en) | Novel binder-drug conjugates (adcs) and their use | |
| JP2020506951A5 (https=) | ||
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| WO2015153857A1 (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
| JP2019194209A (ja) | Ｐｓｍａリガンドコンジュゲートによる併用療法 | |
| JPWO2021177438A5 (https=) | ||
| JP2022540395A (ja) | 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法 | |
| JP2019536780A (ja) | Ｍｅｔ抗体薬物複合体 | |
| JP7774882B2 (ja) | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 | |
| JP2018168068A (ja) | 抗ポドプラニン抗体及び抗体薬物複合体 | |
| JP2016540826A5 (https=) | ||
| KR20250160431A (ko) | 방사성 금속 표지 항체, 방사성 의약, 및 화합물 | |
| JPWO2020089687A5 (https=) |